Blood in Semen and Prostate Cancer Risk
Hematospermia (blood in semen) is rarely a sign of prostate cancer, occurring in only 3.5-5.7% of cases, but men ≥40 years old presenting with this symptom should undergo prostate cancer screening with PSA testing and digital rectal examination 1, 2.
Risk Stratification by Age
The risk of malignancy with hematospermia is dramatically age-dependent:
- Under 40 years: Essentially negligible cancer risk (0.01% in one large study) 3
- 40 years and older: Cancer detection rate of 5.3-13.7%, with prostate cancer being the predominant malignancy 2, 3, 4
The most recent ACR guidelines (2025) explicitly state that patients ≥40 years of age presenting with hematospermia should be screened for prostate cancer 1. This recommendation is based on the substantially higher prevalence of malignancy in this age group.
Clinical Approach
For Men ≥40 Years Old:
Mandatory screening includes:
- Prostate-specific antigen (PSA) testing
- Digital rectal examination (DRE)
Consider prostate MRI when:
- PSA and DRE are normal but hematospermia persists
- MRI significantly improves detection of clinically significant prostate cancer in this setting (OR 14.15, p=0.001) 5
For Men <40 Years Old:
- Reassurance is appropriate after excluding hematuria with urinalysis
- Extensive workup is not indicated given the extremely low cancer risk 3
Important Caveats
Most hematospermia is benign: The vast majority of cases (>94%) are due to infectious/inflammatory processes (prostatitis, seminal vesiculitis) or are idiopathic 1. However, the anxiety this symptom causes patients—who typically fear cancer—justifies age-appropriate screening.
Duration doesn't predict cancer: Persistent or recurrent hematospermia is NOT an independent predictor of malignancy (OR 0.20, p=0.15) 5. Don't be falsely reassured by brief episodes or falsely alarmed by prolonged ones.
Other investigations have poor yield: Flexible cystoscopy, renal ultrasound, and IVU detected significant new pathology requiring intervention in only 0.4% of cases 6. These should not be performed routinely unless there are additional concerning symptoms like hematuria.
When Cancer is Detected
When prostate cancer is diagnosed in the setting of hematospermia 2:
- Most cases (77%) are organ-confined (pT2 disease)
- The cancer is often clinically significant (Gleason ≥7 in 17% of biopsied patients) 5
- Hematospermia represents an independent predictor of prostate cancer after adjusting for age, PSA, and DRE (OR 1.73, p=0.054) 2
The bottom line: While hematospermia is usually benign, it warrants prostate cancer screening in men 40 and older through PSA and DRE, with consideration of MRI if initial screening is negative but symptoms persist 1, 5.